Business Wire

Foundation Medicine Expands Immunohistochemistry (IHC) Testing Portfolio to Include MET IHC Testing

BOSTON--(BUSINESS WIRE)--Foundation Medicine, Inc., a genomics company committed to transforming cancer care, today announced that it has expanded its immunohistochemistry (IHC) test offerings to ...
Seeking Alpha

Guardant Health Introduces Comprehensive Immunohistochemistry Testing for Solid Tumors

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE)-- ...
KXAN

Caris Life Sciences Provides MET Immunohistochemistry Testing as Standard of Care for Non-Squamous Non-Small Cell Lung Cancer Patients

IRVING, Texas, May 12, 2025 /PRNewswire/ -- Caris Life Sciences®(Caris), a leading next-generation AI TechBio company and precision medicine pioneer, performs MET Immunohistochemistry (IHC) testing as ...
Insider Monkey

Guardant Health (GH) introduces IHC Solid Tumor Testing to its Portfolio

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests. This addition will help oncologists identify the ...
The American Journal of Managed Care

Real-World Insights on Biomarker Testing Patterns and Implications for mNSCLC Therapy Selection

Background: Biomarker testing is essential for guiding first-line treatment decisions in metastatic non–small cell lung cancer (mNSCLC). Despite guideline recommendations, real-world testing patterns ...
Nasdaq

PathAI to Present Machine Learning-based Quality Control Tool for HER2 Testing in Breast Cancer at the American Society of Clinical Oncology Virtual Scientific Program 2021

Collaboration to produce a machine learning (ML)-based tool that automatically analyzes images of HER2 immunohistochemistry (IHC)-stained tissue slides and reports metrics that can be used to monitor ...
Morningstar

Boston Cell Standards: Calibration Transforms Accuracy in HER2-Low Breast Cancer Testing

Boston Cell Standards today announced the publication of the CASI-01 study in Lancet: eBioMedicinedemonstrating that calibration dramatically improves the accuracy and reproducibility of ...
Nasdaq

Tempus Next Launches New Algorithm to Close Care Gaps in Guideline-Directed IHC Testing, Starting with HER2

New RNA-based algorithm is now available with the xR assay “This program is truly the intersection of all three of our business units – genomics, AI applications, and data – leveraging our deep ...
Business Wire

Genomic Testing Cooperative to Present at the AACR 2023 Meeting Demonstrating Reliability of Targeted Transcriptomic Profiling in Predicting Levels of HER2, ER, PD-L1 and Other ...

IRVINE, Calif.--(BUSINESS WIRE)--Genomic Testing Cooperative, LCA (GTC) announced that it will be presenting data at the 2023 American Association of Cancer Research (AACR) Annual Meeting ...
Houston Chronicle

Antemortem testing for chronic wasting disease resumes at TVMDL

The Texas A&M Veterinary Medical Diagnostic Laboratory has resumed immunohistochemistry (IHC) testing for chronic wasting disease after a national supply shortage of reagents grinded the process to a ...